Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:02 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Mifepristone and Two Doses of Misoprostol for Abortion at 11&12 Weeks
NCT05119439 · Gynuity Health Projects · PHASE4 · terminated · last registry update 2023-07-25 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Enrollment” | – | Registry record, Gynuity Health Projects |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against NR3C1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-11Phase 3 first posted: Fayoum University, Methylprednisolone + Dexamethasone (NCT06496997)
- 2024-03-12Results posted on the registry: National Cancer Institute (NCI), Clofarabine + Cyclophosphamide (NCT02883049)
- 2023-11-18Phase 3 first posted: Merck Sharp & Dohme LLC, Opevesostat + Abiraterone acetate (NCT06136624)
- 2023-11-18Phase 3 first posted: Merck Sharp & Dohme LLC, Opevesostat + Dexamethasone (NCT06136650)
- 2023-11-09Phase 3 first posted: Actinogen Medical, Xanamem + Placebo (NCT06125951)
- 2023-08-08Phase 3 first posted: Wake Forest University Health Sciences, Betamethasone dipropionate 0.05% + Tapinarof (NCT05981118)
- 2023-07-19Results posted on the registry: Weill Medical College of Cornell University, 177Lu-J591 + Ketoconazole (NCT00859781)
- 2023-06-27Results posted on the registry: National Cancer Institute (NCI), Ipilimumab + Nivolumab (NCT03816332)
- 2023-06-07Results posted on the registry: St. Jude Children's Research Hospital, ITMHA + Dexamethasone (NCT02553460)
- 2023-05-31Results posted on the registry: National Cancer Institute (NCI), Bleomycin Sulfate + Brentuximab Vedotin (NCT02166463)
- 2023-04-19Results posted on the registry: City of Hope Medical Center, Brentuximab Vedotin + Cyclophosphamide (NCT03113500)
- 2023-01-25Results posted on the registry: National Cancer Institute (NCI), Blinatumomab + Dasatinib (NCT02143414)
- 2023-01-09Phase 3 first posted: National Cancer Institute (NCI), Bleomycin Sulfate + Brentuximab Vedotin (NCT05675410)
- 2022-12-06Results posted on the registry: National Cancer Institute (NCI), Asparaginase + Blinatumomab (NCT02101853)
- 2022-09-10Phase 3 first posted: Wei-Che Ko, Squaric Acid Dibutyl Ester + Dupilumab (NCT05535738)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision